Antipsychotic drug-induced changes in metabolism;Metabolische nebenwirkungen von antipsychotika der neuen generation

Wiener Klinische Wochenschrift

Volumn 118, Issue 7-8, 2006, Pages 196-206

  Engl, Julia ^a   Tschoner, Alexander ^a   Laimer, Markus ^a   Rettenbacher, Maria ^b   Fleischhacker, W Wolfgang ^b   Patsch, Josef R ^a   Ebenbichler, Christoph ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

Author keywords

Atypical antipsychotics; Diabetes; Lipids; Metabolism; New generation antipsychotics

Indexed keywords

AMANTADINE; AMISULPRIDE; ARIPIPRAZOLE; CLOZAPINE; INSULIN; INSULIN SENSITIZING AGENT; METFORMIN; NEUROLEPTIC AGENT; NIZATIDINE; OLANZAPINE; PIOGLITAZONE; QUETIAPINE; RISPERIDONE; SERTINDOLE; SIBUTRAMINE; TETRAHYDROLIPSTATIN; TOPIRAMATE; ZIPRASIDONE; ZOTEPINE;

BODY FAT; BODY FAT DISTRIBUTION; DIABETES MELLITUS; DISORDERS OF CARBOHYDRATE METABOLISM; DISORDERS OF LIPID AND LIPOPROTEIN METABOLISM; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; EXTRAPYRAMIDAL SYMPTOM; GLUCOSE HOMEOSTASIS; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERPROLACTINEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID METABOLISM; MENTAL DISEASE; METABOLIC DISORDER; METABOLISM; OBESITY; PATHOPHYSIOLOGY; RECURRENT DISEASE; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; TARGET ORGAN; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS; HUMANS; METABOLIC DISEASES; PSYCHOTIC DISORDERS; RISK ASSESSMENT; RISK FACTORS;

EID: 33745762316     PISSN: 00435325     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00508-006-0584-3     Document Type: Review

References (90)

1. Mueser KT, McGurk SR (2004) Schizophrenia. Lancet 363 (9426): 2063-2072
2. Widschwendter CG, Fleischhacker WW (2005) Pathophysiology of schizophrenia and its impact on pharmacotherapy. Fortschr Neurol Psychiatr 73 [Suppl 1]: S 32-37
3. Almeida OP, Howard RJ, Levy R, David AS (1995) Psychotic states arising in late life (late paraphrenia) psychopathology and nosology. Br J Psychiatry 166 (2): 205-214
4. Miyamoto S, Lieberman JA, Fleischhacker WW, Aoba A, Marder SR (2003) Antipsychotic drugs. In: Tasman AJK, Lieberman JA (eds) Psychiatry. 2nd edn. pp 1928-1964
5. (2004) Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27 (2): 596-601
6. Farah A (2005) Atypicality of atypical antipsychotics. Prim Care Companion J Clin Psychiatry 7 (6): 268-274
7. Arnt J, Skarsfeldt T (1998) Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 18 (2): 63-101
8. Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, De Loore K, Leysen JE (1996) Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl) 124 (1-2): 57-73
9. Goldstein JM (2000) The new generation of antipsychotic drugs: how atypical are they? Int J Neuropsychopharmacol 3 (4): 339-349
10. Kapur S, Seeman P (2001) Does fast dissociation from the dopamine d (2) receptor explain the action of atypical antipsychotics? A new hypothesis. Am J Psychiatry 158 (3): 360-369
11. Kapur S, Zipursky R, Jones C, Shammi CS, Remington G, Seeman P (2000) A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Arch Gen Psychiatry 57 (6): 553-559
12. Fleischhacker WW (2005) Aripiprazole. Expert Opin Pharmacother 6 (12): 2091-2101
13. Moller HJ (2005) Antipsychotic and antidepressive effects of second generation antipsychotics: two different pharmacological mechanisms? Eur Arch Psychiatry Clin Neurosci 255 (3): 190-201
14. Lewis R, Bagnall AM, Leitner M (2005) Sertindole for schizophrenia. Cochrane Database Syst Rev 3: CDOO1715
15. Melkersson K (2005) Differences in prolactin elevation and related symptoms of atypical antipsychotics in schizophrenic patients. J Clin Psychiatry 66 (6): 761-767
16. Haddad PM, Wieck A (2004) Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 64 (20): 2291-2314
17. Stevens JR, Kymissis PI, Baker AJ (2005) Elevated prolactin levels in male youths treated with risperidone and quetiapine. J Child Adolesc Psychopharmacol 15 (6): 893-900
18. Hummer M, Huber J (2004) Hyperprolactinaemia and antipsychotic therapy in schizophrenia. Curr Med Res Opin 20 (2): 189-197
19. Wang PS, Walker AM, Tsuang MT, Orav EJ, Glynn RJ, Levin R, Avorn J (2002) Dopamine antagonists and the development of breast cancer. Arch Gen Psychiatry 59 (12): 1147-1154
20. Allison DB, Fontaine KR, Heo M, Mentore JL, Cappelleri JC, Chandler LP, Weiden PJ, Cheskin LJ (1999) The distribution of body mass index among individuals with and without schizophrenia. J Clin Psychiatry 60 (4): 215-220
21. Kurzthaler I, Fleischhacker WW (2001) The clinical implications of weight gain in schizophrenia. J Clin Psychiatry 62 [Suppl 7]: 32-37
22. Henderson DC, Cagliero E, Gray C, Nasrallah RA, Hayden DL, Schoenfeld DA, Goff DC (2000) Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am J Psychiatry 157 (6): 975-981
23. Hummer M, Kemmler G, Kurz M, Kurzthaler I, Oberbauer H, Fleischhacker WW (1995) Weight gain induced by clozapine. Eur Neuropsychopharmacol 5 (4): 437-440
24. Gupta S, Droney T, Al-Samarrai S, Keller P, Frank B (1998) Olanzapine-induced weight gain. Ann Clin Psychiatry 10 (1): 39
25. Eder U, Mangweth B, Ebenbichler C, Weiss E, Hofer A, Hummer M, Kemmler G, Lechleitner M, Fleischhacker WW (2001) Association of olanzapine-induced weight gain with an increase in body fat. Am J Psychiatry 158 (10): 1719-1722
26. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, Weiden PJ (1999) Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 156 (11): 1686-1696
27. Newcomer JW (2005) Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 19 [Suppl 1]: 1-93
28. Wetterling T, Pest S, Mussigbrodt H, Weber B (2004) Bodyweight in inpatients with schizophrenia. Psychiatr Prax 31 (5): 250-254
29. Centorrino F, Wurtman JJ, Duca KA, Fellman VH, Fogarty KV, Berry JM, Guay DM, Romeling M, Kidwell J, Baldessarini RJ (2006) Weight loss in overweight patients maintained on atypical antipsychotic agents. Int J Obes (Lond) advance online publication
30. Ananth J, Venkatesh R, Burgoyne K, Gadasalli R, Binford R, Gunatilake S (2004) Atypical antipsychotic induced weight gain: pathophysiology and management. Ann Clin Psychiatry 16 (2): 75-85
31. Dourish CT (1995) Multiple serotonin receptors: opportunities for new treatments for obesity? Obes Res 3 [Suppl 4]: 449S-462S
32. Heal DJ, Aspley S, Prow MR, Jackson HC, Martin KF, Cheetham SC (1998) Sibutramine: a novel anti-obesity drug. A review of the pharmacological evidence to differentiate it from d-amphetamine and d-fenfluramine. Int J Obes Relat Metab Disord 22 [Suppl 1]: S18-28; discussion S29
33. Strombom U, Krotkiewski M, Blennow K, Mansson JE, Ekman R, Bjorntorp P (1996) The concentrations of monoamine metabolites and neuropeptides in the cerebrospinal fluid of obese women with different body fat distribution. Int J Obes Relat Metab Disord 20 (4): 361-368
34. Li Z, Maglione M, Tu W, Mojica W, Arterburn D, Shugarman LR, Hilton L, Suttorp M, Solomon V, Shekelle PG, Morton SC (2005) Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med 142 (7): 532-546
35. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM (1994) Positional cloning of the mouse obese gene and its human homologue. Nature 372 (6505): 425-432
36. Sinha MK, Opentanova I, Ohannesian JP, Kolaczynski JW, Heiman ML, Hale J, Becker GW, Bowsher RR, Stephens TW, Caro JF (1996) Evidence of free and bound leptin in human circulation. Studies in lean and obese subjects and during short-term fasting. J Clin Invest 98 (6): 1277-1282
37. Engl J, Hanusch-Enserer U, Prager R, Patsch JR, Ebenbichler C (2005) The metabolic syndrome: effects of a pronounced weight loss induced by bariatric surgery. Wien Klin Wochenschr 117 (7-8): 243-254
38. Kraus T, Haack M, Schuld A, Hinze-Seich D, Kuhn M, Uhr M, Pollmacher T (1999) Body weight and leptin plasma levels during treatment with antipsychotic drugs. Am J Psychiatry 156 (2): 312-314
39. Bromel T, Blum WF, Ziegler A, Schulz E, Bender M, Fleischhaker C, Remschmidt H, Krieg JC, Hebebrand J (1998) Serum leptin levels increase rapidly after initiation of clozapine therapy. Mol Psychiatry 3 (1): 76-80
40. Baptista T, Beaulieu S (2002) Are leptin and cytokines involved in body weight gain during treatment with antipsychotic drugs? Can J Psychiatry 47 (8): 742-749
41. Palik E, Birkas KD, Faludi G, Karadi I, Cseh K (2005) Correlation of serum ghrelin levels with body mass index and carbohydrate metabolism in patients treated with atypical antipsychotics. Diabetes Res Clin Pract 68 [Suppl 1]: S60-64
42. Himmerich H, Fulda S, Kunzel HE, Pfennig A, Dzaja A, Cummings DE, Pollmacher T (2005) Ghrelin plasma levels during psychopharmacological treatment. Neuropsychobiology 52 (1): 11-16
43. Buse JB, Cavazzoni P, Hornbuckle K, Hutchins D, Breier A, Jovanovic L (2003) A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States. J Clin Epidemiol 56 (2): 164-170
44. Cohen D (2004) Atypical antipsychotics and new onset diabetes mellitus. An overview of the literature. Pharmacopsychiatry 37 (1): 1-11
45. Brugman NJ, Cohen D, de Vries RH (2000) Diabetes mellitus after treatment with clozapine. Ned Tijdschr Geneeskd 144 (9): 437-439
46. Pierides M (1997) Clozapine monotherapy and ketoacidosis. Br J Psychiatry 171: 90-91
47. Koller EA, Weber J, Doraiswamy PM, Schneider BS (2004) A survey of reports of quetiapine-associated hyperglycemia and diabetes mellitus. J Clin Psychiatry 65 (6): 857-863
48. Koro CE, Fedder DO, L'Italien GJ, Weiss SS, Magder LS, Kreyenbuhl J, Revicki DA, Buchanan RW (2002) Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. BMJ 325 (7358): 243
49. Lindenmayer JP, Czobor P, Volavka J, Citrome L, Sheitman B, McEvoy JP, Cooper TB, Chakos M, Lieberman JA (2003) Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry 160 (2): 290-296
50. Ebenbichler CF, Laimer M, Eder U, Mangweth B, Weiss E, Hofer A, Hummer M, Kemmler G, Lechleitner M, Patsch JR, Fleischhacker WW (2003) Olanzapine induces insulin resistance: results from a prospective study. J Clin Psychiatry 64: 1436-1439
51. Laimer M, Ebenbichler CF, Kranebitter M, Eder U, Mangweth B, Weiss E, Hofer A, Hummer M, Kemmler G, Lechleitner M, Patsch JR, Fleischhacker WW (2005) Olanzapine-induced hyperglycemia: role of humoral insulin resistance-inducing factors. J Clin Psychopharmacol 25 (2): 183-185
52. Henderson DC, Cagliero E, Copeland PM, Borba CP, Evins E, Hayden D, Weber MT, Anderson EJ, Allison DB, Daley TB, Schoenfeld D, Goff DC (2005) Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psychiatry 62 (1): 19-28
53. Sowell MO, Mukhopadhyay N, Cavazzoni P, Shankar S, Steinberg HO, Breier A, Beasley CM Jr, Dananberg J (2002) Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or placebo. J Clin Endocrinol Metab 87 (6): 2918-2923
54. Brown RR, Estoup MW (2005) Comparison of the metabolic effects observed in patients treated with ziprasidone versus olanzapine. Int Clin Psychopharmacol 20 (2): 105-112
55. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353 (12): 1209-1223
56. Melkersson KI, Hulting AL, Brismar KE (2000) Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. J Clin Psychiatry 61 (10): 742-749
57. Wirshing DA, Spellberg BJ, Erhart SM, Marder SR, Wirshing WC (1998) Novel antipsychotics and new onset diabetes. Biol Psychiatry 44 (8): 778-783
58. McIntyre RS, Mancini DA, Basile VS (2001) Mechanisms of antipsychotic-induced weight gain. J Clin Psychiatry 62 [Suppl 23]: 23-29
59. Melkersson K, Khan A, Hilding A, Hulting AL (2001) Different effects of antipsychotic drugs on insulin release in vitro. Eur Neuropsychopharmacol 11 (5): 327-332
60. Melkersson K (2004) Clozapine and olanzapine, but not conventional antipsychotics, increase insulin release in vitro. Eur Neuropsychopharmacol 14 (2): 115-119
61. Griffin ME, Marcucci MJ, Cline GW, Bell K, Barucci N, Lee D, Goodyear LJ, Kraegen EW, White MF, Shulman GI (1999) Free fatty acid-induced insulin resistance is associated with activation of protein kinase C theta and alterations in the insulin signaling cascade. Diabetes 48 (6): 1270-1274
62. Yu C, Chen Y, Cline GW, Zhang D, Zong H, Wang Y, Bergeron R, Kim JK, Cushman SW, Cooney GJ, Atcheson B, White MF, et al (2002) Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle. J Biol Chem 277 (52): 50230-50236
63. Belfort R, Mandarino L, Kashyap S, Wirfel K, Pratipanawatr T, Berria R, Defronzo RA, Cusi K (2005) Dose-response effect of elevated plasma free fatty acid on insulin signaling. Diabetes 54 (6): 1640-1648
64. Engl J, Laimer M, Niederwanger A, Kranebitter M, Starzinger M, Pedrini MT, Fleischhacker WW, Patsch JR, Ebenbichler CF (2005) Olanzapine impairs glycogen synthesis and insulin signaling in L6 skeletal muscle cells. Mol Psychiatry 10 (12): 1089-1096
65. Gilles M, Wilke A, Kopf D, Nonell A, Lehnert H, Deuschle M (2005) Antagonism of the serotonin (5-HT)-2 receptor and insulin sensitivity: implications for atypical antipsychotics. Psychosom Med 67 (5): 748-751
66. Patsch JR, Miesenbock G, Hopferwieser T, Muhlberger V, Knapp E, Dunn JK, Gotto AM, Jr, Patsch W (1992) Relation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state. Arterioscler Thromb 12 (11): 1336-1345
67. Wirshing DA, Boyd JA, Meng LR, Ballon JS, Marder SR, Wirshing WC (2002) The effects of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry 63 (10): 856-865
68. Koro CE, Fedder DO, L'Italien GJ, Weiss S, Magder LS, Kreyenbuhl J, Revicki D, Buchanan RW (2002) An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients. Arch Gen Psychiatry 59 (11): 1021-1026
69. Brown CD, Higgins M, Donato KA, Rohde FC, Garrison R, Obarzanek E, Ernst ND, Horan M (2000) Body mass index and the prevalence of hypertension and dyslipidemia. Obes Res 8 (9): 605-619
70. Meyer JM (2001) Novel antipsychotics and severe hyperlipidemia. J Clin Psychopharmacol 21 (4): 369-374
71. Kinon BJ, Basson BR, Gilmore JA, Tollefson GD (2001) Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J Clin Psychiatry 62 (2): 92-100
72. Baptista T, Lacruz A, de Mendoza S, Mendoza Guillen JM, Silvera R, Angeles F, Mendoza MT, Hernandez L (2000) Body weight gain after administration of antipsychotic drugs: correlation with leptin, insulin and reproductive hormones. Pharmacopsychiatry 33 (3): 81-88
73. De Hert MA, van Winkel R, Van Eyck D, Hanssens L, Wampers M, Scheen A, Peuskens J (2006) Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophr Res 83 (1): 87-93
74. Ryan MC, Flanagan S, Kinsella U, Keeling F, Thakore JH (2004) The effects of atypical antipsychotics on visceral fat distribution in first episode, drug-naive patients with schizophrenia. Life Sci 74 (16): 1999-2008
75. Weber M, Wyne K (2006) A cognitive/behavioral group intervention for weight loss in patients treated with atypical antipsychotics. Schizophr Res 83 (1): 95-101
76. Weintraub M, Rubio A, Golik A, Byrne L, Scheinbaum ML (1991) Sibutramine in weight control: a dose-ranging, efficacy study. Clin Pharmacol Ther 50 (3): 330-337
77. Henderson DC, Copeland PM, Daley TB, Borba CP, Cather C, Nguyen DD, Louie PM, Evins AE, Freudenreich O, Hayden D, Goff DC (2005) A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain. Am J Psychiatry 162 (5): 954-962
78. Himmerich H, Schuld A, Pollmacher T (2004) Weight gain during treatment with antipsychotics: clinical relevance, pathophysiology, and therapeutical strategies. Psychiatr Prax 31 [Suppl 2]: S233-237
79. Anghelescu I, Klawe C, Szegedi A (2002) Add-on combination and maintenance treatment: case series of five obese patients with different eating behavior. J Clin Psychopharmacol 22 (5): 521-524
80. Erfurth A, Kuhn G (2000) Topiramate monotherapy in the maintenance treatment of bipolar I disorder: effects on mood, weight and serum lipids. Neuropsychobiology 42 [Suppl 1]: 50-51
81. Kim JH, Yim SJ, Nam JH (2006) A 12-week, randomized, open-label, parallel-group trial of topiramate in limiting weight gain during olanzapine treatment in patients with schizophrenia. Schizophr Res 82 (1): 115-117
82. Floris M, Lejeune J, Deberdt W (2001) Effect of amantadine on weight gain during olanzapine treatment. Eur Neuropsychopharmacol 11 (2): 181-182
83. Graham KA, Gu H, Lieberman JA, Harp JB, Perkins DO (2005) Double-blind, placebo-controlled investigation of amantadine for weight loss in subjects who gained weight with olanzapine. Am J Psychiatry 162 (9): 1744-1746
84. Sacchetti E, Guarneri L, Bravi D (2000) H(2) antagonist nizatidine may control olanzapine-associated weight gain in schizophrenic patients. Biol Psychiatry 48 (2): 167-168
85. Atmaca M, Kuloglu M, Tezcan E, Ustundag B (2003) Nizatidine treatment and its relationship with leptin levels in patients with olanzapine-induced weight gain. Hum Psychopharmacol 18 (6): 457-461
86. Cavazzoni P, Tanaka Y, Roychowdhury SM, Breier A, Allison DB (2003) Nizatidine for prevention of weight gain with olanzapine: a double-blind placebo-controlled trial. Eur Neuropsychopharmacol 13 (2): 81-85
87. Morrison JA, Cottingham EM, Barton BA (2002) Metformin for weight loss in pediatric patients taking psychotropic drugs. Am J Psychiatry 159 (4): 655-657
88. Edlinger M, Ebenbichler C, Rettenbacher M, Fleischhacker WW (2006) Therapy of antipsychotic-associated diabetes mellitus with pioglitazone, a case series. Schizophrenia Research 81 [Suppl 1]: 133-134
89. Giner V, Munoz R, Redon J (2002) Risperidone and severe cerivastatin-induced rhabdomyolysis. J Intern Med 251 (2): 177-178
90. Webber MA, Mahmud W, Lightfoot JD, Shekhar A (2004) Rhabdomyolysis and compartment syndrome with coadministration of risperidone and simvastatin. J Psychopharmacol 18 (3): 432-434